Stem cells are a relevant source of information about cellular differentiation, molecular
processes and tissue homeostasis, but also one of the most putative biological tools to treat …

The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous
leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell …

The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell
transplantation (HSCT) for chronic myeloid leukemia (CML). Information on the current use …

This study reports outcomes of allogeneic hematopoietic stem cell transplantation with
reduced-intensity conditioning (RIC) in 186 patients with chronic myeloid leukemia (CML) …

Chronic myeloid leukemia provides an illustrative disease model for both molecular
pathogenesis of cancer and rational drug therapy. Chronic myeloid leukemia is a clonal …

A total of 72 patients with Ph-positive CML in first chronic phase were followed during a 6-
year period in two different institutions in México. Among them, 22 were given a reduced …

Purpose of Review A large number of chronic myeloid leukemia (CML) patients receiving
tyrosine kinase inhibitors (TKIs) can now enjoy a deep molecular control of the disease and …

A total of 24 patients (median age 58; range, 27–71 years) with chronic myeloid leukemia
(CML) in first chronic (CP1)(n= 14), second chronic (n= 4), or accelerated phase (n= 6) who …

Using a reduced-intensity stem cell transplantation (RIST) schedule, 24 patients with
Philadelphia (Ph1)(+) chronic myelogenous leukemia (CML) in first chronic phase (CP) were …

Allogeneic hematopoietic cell transplantation (HCT) was originally developed to allow
delivery of myeloablative doses of chemotherapy and radiotherapy. With better …